Cargando…
Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial
Background Among medically ill patients treated with thromboprophylaxis, betrixaban was not associated with an increase in major bleeding compared with enoxaparin, but an increase in clinically relevant non-major (CRNM) bleeding was observed. The aim of this analysis is to describe the severity and...
Autores principales: | Yee, Megan K., Gibson, C. Michael, Nafee, Tarek, Kerneis, Mathieu, Daaboul, Yazan, Korjian, Serge, Chi, Gerald, AlKhalfan, Fahad, Hernandez, Adrian F., Hull, Russell D., Cohen, Alexander T., Goldhaber, Samuel Z. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524922/ https://www.ncbi.nlm.nih.gov/pubmed/31249989 http://dx.doi.org/10.1055/s-0039-1685496 |
Ejemplares similares
-
Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial
por: Gibson, C. Michael, et al.
Publicado: (2018) -
Machine learning to predict venous thrombosis in acutely ill medical patients
por: Nafee, Tarek, et al.
Publicado: (2020) -
Comparison of Fatal or Irreversible Events With Extended‐Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy
por: Gibson, C. Michael, et al.
Publicado: (2017) -
Pheochromocytoma Presenting as Partial HELLP Syndrome
por: Daaboul, Yazan, et al.
Publicado: (2015) -
Safety and Efficacy of Rivaroxaban When Added to Aspirin Monotherapy Among Stabilized Post‐Acute Coronary Syndrome Patients: A Pooled Analysis Study of ATLAS ACS‐TIMI 46 and ATLAS ACS 2‐TIMI 51
por: Gibson, William J., et al.
Publicado: (2019)